首頁 > 市場調查報告書 > 製藥

精神疾病

市場調查報告書

商品編碼

2103089

全球憂鬱症臨床試驗現況：趨勢與分析（2026 年版）

Global Depression Clinical Trials Landscape: Developments and Analysis, 2026 Update

出版日期: 2026年07月17日 | 出版商:

Knowledge Sourcing Intelligence | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

隨著製藥公司、生技公司、學術機構和合約研究組織（CRO）加速開發創新憂鬱症，全球憂鬱症臨床試驗格局正經歷重大變革。憂鬱症仍然是全球最常見的精神疾病之一，影響數億人，並嚴重影響患者的殘疾程度、醫療保健服務取得以及生活品質。人們對起效更快、療效更佳、更個人化的療法的需求依然存在，這促使針對多種治療方法的臨床研究活動日益活躍，並造就了一個充滿活力且競爭激烈的市場環境。

臨床試驗生態系統正從傳統的抗憂鬱症擴展到包括新型作用機制的藥物，例如NMDA受體調變器、GABA受體調變器、迷幻藥療法、靶向神經發炎的療法、Orexin受體拮抗劑以及精準精神病學方法。研究人員也正在整合生物標記、人工智慧、數位健康技術和分散式臨床試驗模式，以提高受試者招募、治療監測和試驗效率。這些創新正在改變憂鬱症藥物的研發方式，並緩解傳統精神病臨床研究中一些常見的操作難題。

人們對精神疾病的認知不斷提高，政府對行為醫學的投入不斷增加，以及精神科服務的可近性不斷改善，都進一步推動了憂鬱症的臨床研究。監管機構持續鼓勵創新，透過快速研發途徑開發針對難治性憂鬱症和其他嚴重憂鬱症障礙的治療方法。同時，製藥公司、研究機構和數位醫療服務提供者之間合作的加強，正在提升全球研究能力，並加速治療方法的創新。

此外，該市場越來越關注以患者為中心的試驗設計、真實世界數據 (REW) 的生成以及數位化監測技術。遠端患者評估、行動醫療應用程式、穿戴式裝置和電子患者報告結局 (ePRO) 正在改進數據收集，同時提高患者參與率和保留率。隨著神經科學研究的進展和新型治療平台的不斷湧現，憂鬱症臨床試驗市場預計將在預測期內保持持續成長。

市場促進因素

全球憂鬱症負擔日益加重

憂鬱症盛行率的不斷上升仍然是推動臨床研究活動的主要動力。重度憂鬱症患者人數在各個年齡層持續成長，因此對更有效的治療方法提出了更高的要求。

人們認知到憂鬱症是一個重大的公共衛生問題，這刺激了對創新療法和臨床研究計畫的投入。

擴大新治療藥物的研發管線

隨著研發人員針對多種生物路徑療法的研究不斷深入，憂鬱症治療藥物的研發管線也日益多元化。包括麩胺酸藥物、迷幻療法、標靶神經發炎的藥物以及精準精神病學方法在內的新型化合物，正逐步進入臨床開發階段。

隨著這條研發管線的擴展，全球範圍內進行的臨床試驗的數量和複雜性也不斷增加。

精準精神醫學的進展

在憂鬱症研究中，基於生物標記的患者篩選和個人化治療策略的重要性日益凸顯。精準精神病學旨在透過識別最有可能從特定治療中獲益的患者亞群來改善治療效果。

引入基於生物標記的試驗設計，既提高了臨床開發的效率，也支持了個人化醫療的發展。

數位健康科技的整合

數位技術正在透過遠端患者監護、電子評估、穿戴式裝置、人工智慧和行動醫療應用程式改變憂鬱症的臨床試驗。

這些創新有助於提高患者參與度，改善數據質量，並支持在地理位置分散的人群中實施分散式臨床試驗。

加大對心理健康研究的投資

各國政府、私人投資者、製藥公司和非營利組織都在不斷增加對精神健康研究和開發的投入。公眾意識的提高和對精神疾病意識的加深，為擴大臨床開發活動創造了有利條件。

增加的投資將支持早期藥物研發計畫和後期跨國臨床試驗。

市場限制因素

安慰劑效應率高

在憂鬱症的臨床試驗中，安慰劑效應往往很高，這使得證明具有統計意義的治療效果變得更加困難。

這項挑戰增加了研發風險，並可能導致臨床試驗失敗率升高。

疾病異質性

憂鬱症是一種高度異質性的疾病，其生物機制、症狀表現和治療反應各不相同。患者的個別差異使臨床試驗設計複雜化，也為確定一致的治療結果帶來了挑戰。

為了解決這些複雜問題，研究人員繼續探索基於生物標記的方法。

漫長而高成本的開發過程

精神疾病的臨床試驗需要密切監測患者、大規模的受試者群體、較長的追蹤期以及複雜的療效評估。這些要求增加了研究成本並延長了研發週期。

小規模的生物技術公司在推動有前景的候選療法進入後期臨床開發階段時，可能會面臨資金方面的挑戰。

The global depression clinical trials landscape is undergoing significant transformation as pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations accelerate the development of innovative therapies for depressive disorders. Depression remains one of the most prevalent mental health conditions worldwide, affecting hundreds of millions of people and contributing substantially to disability, healthcare utilization, and reduced quality of life. The persistent unmet need for faster-acting, more effective, and personalized therapies has intensified clinical research activity across multiple therapeutic approaches, creating a dynamic and competitive development environment.

The clinical trial ecosystem has expanded beyond conventional antidepressants to include novel mechanisms of action such as NMDA receptor modulators, GABA receptor modulators, psychedelic-assisted therapies, neuroinflammation-targeted treatments, orexin receptor antagonists, and precision psychiatry approaches. Researchers are also integrating biomarkers, artificial intelligence, digital health technologies, and decentralized clinical trial models to improve patient recruitment, treatment monitoring, and trial efficiency. These innovations are reshaping depression drug development and reducing some of the operational challenges traditionally associated with psychiatric clinical research.

Growing awareness of mental health disorders, increasing government investment in behavioral healthcare, and improving access to psychiatric services are further supporting expansion of depression clinical research. Regulatory agencies continue to encourage innovation through expedited development pathways for therapies addressing treatment-resistant depression and other severe depressive disorders. At the same time, greater collaboration between pharmaceutical companies, research institutions, and digital health providers is strengthening global research capabilities and accelerating therapeutic innovation.

The market is also witnessing increased emphasis on patient-centric trial designs, real-world evidence generation, and digital monitoring technologies. Remote patient assessments, mobile health applications, wearable devices, and electronic patient-reported outcomes are improving data collection while enhancing patient participation and retention. As neuroscience research advances and novel therapeutic platforms continue to emerge, the depression clinical trials landscape is expected to experience sustained growth throughout the forecast period.

Market Drivers

Rising Global Burden of Depression

The increasing prevalence of depression remains the primary driver of clinical research activity. Major depressive disorder continues to affect a growing patient population across all age groups, generating significant demand for improved therapeutic options.

Growing recognition of depression as a major public health concern is encouraging greater investment in innovative treatment development and clinical research programs.

Expanding Pipeline of Novel Therapeutics

The depression treatment pipeline has become increasingly diversified as developers investigate therapies targeting multiple biological pathways. Novel compounds including glutamatergic agents, psychedelic therapies, neuroinflammation-targeted drugs, and precision psychiatry approaches are entering clinical development.

This expanding pipeline is increasing the volume and complexity of clinical trials worldwide.

Growth of Precision Psychiatry

Biomarker-guided patient selection and personalized treatment strategies are becoming increasingly important in depression research. Precision psychiatry aims to improve treatment response by identifying patient subgroups most likely to benefit from specific therapies.

The adoption of biomarker-driven trial designs is improving clinical development efficiency while supporting personalized medicine initiatives.

Integration of Digital Health Technologies

Digital technologies are transforming depression clinical trials through remote patient monitoring, electronic assessments, wearable devices, artificial intelligence, and mobile healthcare applications.

These innovations improve patient engagement, enhance data quality, and support decentralized trial execution across geographically diverse populations.

Increasing Investment in Mental Health Research

Governments, private investors, pharmaceutical companies, and nonprofit organizations continue to increase funding for mental health research. Greater public awareness and improved recognition of psychiatric disorders are creating favorable conditions for expanded clinical development activities.

Investment growth is supporting both early-stage discovery programs and late-stage multinational clinical trials.

Market Restraints

High Placebo Response Rates

Depression clinical trials frequently experience elevated placebo response rates, making it more difficult to demonstrate statistically significant treatment benefits.

This challenge increases development risk and may contribute to higher trial failure rates.

Disease Heterogeneity

Depression represents a highly heterogeneous disorder with diverse biological mechanisms, symptom profiles, and treatment responses. Patient variability complicates trial design and creates challenges for identifying consistent therapeutic outcomes.

Researchers continue to explore biomarker-driven approaches to address these complexities.

Long and Costly Development Process

Psychiatric clinical trials require extensive patient monitoring, large study populations, prolonged follow-up periods, and complex efficacy assessments. These requirements increase research costs and extend development timelines.

Smaller biotechnology companies may face financial challenges in advancing promising therapeutic candidates through late-stage clinical development.

Technology and Segment Insights

By Trial Phase

Phase II clinical trials account for a substantial share of the depression clinical development landscape as developers evaluate therapeutic efficacy, safety, dosing strategies, and biomarker responses for emerging treatment candidates.

Phase III studies continue to expand as successful investigational therapies advance toward regulatory submission. Phase I trials remain active due to the continuous introduction of novel compounds targeting previously unexplored neurological and psychiatric pathways.

By Therapeutic Approach

Conventional antidepressants continue to represent an important segment of ongoing clinical research, particularly for optimization of treatment strategies and combination therapies.

Rapid-acting antidepressants, NMDA receptor modulators, psychedelic-assisted therapies, neuroinflammation-targeted agents, orexin receptor antagonists, and GABA receptor modulators represent some of the fastest-growing areas of innovation.

Investigational therapies designed for treatment-resistant depression are receiving particularly strong research interest due to significant unmet clinical needs.

By Study Design

Interventional clinical trials dominate the market, evaluating the safety and efficacy of emerging pharmaceutical therapies and innovative treatment modalities.

Decentralized clinical trials are becoming increasingly common through the integration of telemedicine, mobile health applications, wearable monitoring devices, and electronic patient-reported outcome systems. These technologies improve patient accessibility while supporting efficient trial management.

By Sponsor Type

Pharmaceutical companies account for the largest share of sponsored depression clinical trials due to extensive investment in antidepressant drug development and commercialization.

Biotechnology companies are expanding rapidly through the development of first-in-class therapies targeting novel biological pathways.

Academic institutions, government organizations, nonprofit research centers, and contract research organizations continue to contribute substantially to global depression research through investigator-sponsored studies and collaborative clinical programs.

Regional Insights

North America dominates the global depression clinical trials landscape due to advanced clinical research infrastructure, significant pharmaceutical investment, extensive mental healthcare resources, and strong regulatory support for psychiatric drug development. The United States continues to lead global clinical trial activity for depression.

Europe represents a major market supported by collaborative academic research networks, established pharmaceutical industries, and increasing investment in mental health innovation. Countries including Germany, the United Kingdom, France, Spain, and Italy remain important contributors to multinational depression studies.

Asia Pacific is expected to witness the fastest growth during the forecast period. Expanding healthcare infrastructure, growing mental health awareness, increasing pharmaceutical investment, and improving regulatory frameworks are supporting greater participation in global clinical development programs across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening clinical research capabilities through increased healthcare investment and broader participation in multinational psychiatric trials.

Competitive and Strategic Outlook

The depression clinical trials landscape is characterized by intense competition among pharmaceutical companies, biotechnology innovators, academic research institutions, and contract research organizations. Market participants are focusing on therapies capable of delivering faster onset of action, improved efficacy, fewer adverse effects, and better outcomes for treatment-resistant patients.

Artificial intelligence, digital biomarkers, predictive analytics, decentralized trial technologies, and precision psychiatry are becoming increasingly important competitive differentiators. Companies are also expanding strategic partnerships with academic institutions, digital health providers, and contract research organizations to accelerate clinical development and improve operational efficiency.

Future competition is expected to center on innovative therapeutic mechanisms, biomarker-guided patient selection, personalized medicine approaches, and digital clinical trial platforms capable of improving recruitment, retention, and regulatory success rates.

Conclusion

The global depression clinical trials landscape is positioned for sustained expansion as demand for innovative mental health therapies continues to grow. Rising disease prevalence, expanding therapeutic pipelines, advances in precision psychiatry, increasing adoption of digital clinical technologies, and growing investment in neuroscience research are expected to drive continued market growth. Although challenges including placebo response, disease heterogeneity, and high development costs remain, ongoing innovation in trial design and therapeutic development is creating significant opportunities for future advancement in depression treatment.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Report Scope and Objectives
1.2 Key Findings
1.3 Epidemiology Highlights
1.4 Disease Burden Overview
1.5 Key Regional Insights
1.6 Key Country Insights
1.7 Forecast Highlights (2025-2045)
1.8 Future Outlook

2. Disease Overview

2.1 Introduction to Depression
2.2 Disease Classification
- 2.2.1 Major Depressive Disorder (MDD)
- 2.2.2 Persistent Depressive Disorder (Dysthymia)
- 2.2.3 Treatment-Resistant Depression (TRD)
- 2.2.4 Postpartum Depression
- 2.2.5 Seasonal Affective Disorder (SAD)
- 2.2.6 Depression Associated with Bipolar Disorder
2.3 Disease Pathophysiology
2.4 Risk Factors and Disease Determinants
2.5 Clinical Manifestations
2.6 Disease Severity Classification
- 2.6.1 Mild Depression
- 2.6.2 Moderate Depression
- 2.6.3 Severe Depression
2.7 Diagnostic Pathway Analysis
2.8 Disease Burden Assessment
2.9 Comorbidity Analysis
2.10 Unmet Clinical Needs

3. Epidemiology Methodology and Assumptions

3.1 Epidemiology Study Design
3.2 Data Sources and Validation Framework
3.3 Forecasting Methodology
3.4 Epidemiology Assumptions
3.5 Population Modeling Framework
3.6 Diagnostic Rate Assessment
3.7 Treatment-Seeking Behavior Analysis
3.8 Limitations and Sensitivity Analysis

4. Global Depression Epidemiology Analysis

4.1 Global Epidemiology Overview
- 4.1.1 Total Prevalence
- 4.1.2 Total Incidence
- 4.1.3 Diagnosed Cases
- 4.1.4 Treated Cases
- 4.1.5 Untreated Cases
- 4.1.6 Age-Specific Epidemiology
- 4.1.7 Gender-Specific Epidemiology
- 4.1.8 Severity-Specific Epidemiology
- 4.1.9 Forecast Analysis (2025-2045)
4.2 By Disease Type
- 4.2.1 Major Depressive Disorder (MDD)
- 4.2.2 Persistent Depressive Disorder (Dysthymia)
- 4.2.3 Treatment-Resistant Depression (TRD)
- 4.2.4 Postpartum Depression
- 4.2.5 Seasonal Affective Disorder (SAD)
- 4.2.6 Bipolar Depression
4.3 By Severity
- 4.3.1 Mild Depression
- 4.3.2 Moderate Depression
- 4.3.3 Severe Depression
4.4 By Diagnosis Status
- 4.4.1 Diagnosed Cases
- 4.4.2 Undiagnosed Cases
- 4.4.3 Misdiagnosed Cases
4.5 By Treatment Status
- 4.5.1 Treated Population
- 4.5.2 Untreated Population
- 4.5.3 Treatment-Resistant Population

5. Patient Population Segmentation

5.1 By Disease Type
- 5.1.1 Major Depressive Disorder (MDD)
- 5.1.2 Persistent Depressive Disorder (Dysthymia)
- 5.1.3 Treatment-Resistant Depression (TRD)
- 5.1.4 Postpartum Depression
- 5.1.5 Seasonal Affective Disorder (SAD)
- 5.1.6 Bipolar Depression
5.2 By Gender
- 5.2.1 Male
- 5.2.2 Female
5.3 By Age Group
- 5.3.1 Children (<18 Years)
- 5.3.2 Young Adults (18-24 Years)
- 5.3.3 Adults (25-44 Years)
- 5.3.4 Middle-Aged Adults (45-64 Years)
- 5.3.5 Elderly Population (65+ Years)
5.4 By Severity
- 5.4.1 Mild
- 5.4.2 Moderate
- 5.4.3 Severe
5.5 By Treatment Status
- 5.5.1 Treated Population
- 5.5.2 Untreated Population
- 5.5.3 Treatment-Resistant Population

6. Disease Burden Analysis

6.1 Clinical Burden Assessment
6.2 Social Burden Assessment
6.3 Economic Burden Assessment
6.4 Mortality and Suicide Risk Analysis
6.5 Disability Burden Assessment
6.6 Productivity Loss Analysis
6.7 Healthcare Resource Utilization
6.8 Quality of Life Impact Assessment
6.9 Caregiver Burden Analysis

7. Diagnosis and Patient Journey Analysis

7.1 Symptom Recognition Trends
7.2 Healthcare Seeking Behavior
7.3 Screening and Diagnosis Patterns
7.4 Time to Diagnosis Analysis
7.5 Barriers to Diagnosis
7.6 Referral Pathways
7.7 Treatment Initiation Trends
7.8 Long-Term Disease Management Patterns

8. Geographical Analysis

8.1 North America
- 8.1.1 Total Prevalence
- 8.1.2 Total Incidence
- 8.1.3 Diagnosed Cases
- 8.1.4 Treated Cases
- 8.1.5 Severity Distribution
- 8.1.6 Age-Specific Epidemiology
- 8.1.7 Gender-Specific Epidemiology
- 8.1.8 Forecast Analysis (2025-2045)
- 8.1.9 Epidemiology Growth Drivers
- 8.1.10 Growth Opportunities
8.2 Europe
- 8.2.1 Total Prevalence
- 8.2.2 Total Incidence
- 8.2.3 Diagnosed Cases
- 8.2.4 Treated Cases
- 8.2.5 Severity Distribution
- 8.2.6 Age-Specific Epidemiology
- 8.2.7 Gender-Specific Epidemiology
- 8.2.8 Forecast Analysis (2025-2045)
- 8.2.9 Epidemiology Growth Drivers
- 8.2.10 Growth Opportunities
8.3 Asia-Pacific
- 8.3.1 Total Prevalence
- 8.3.2 Total Incidence
- 8.3.3 Diagnosed Cases
- 8.3.4 Treated Cases
- 8.3.5 Severity Distribution
- 8.3.6 Age-Specific Epidemiology
- 8.3.7 Gender-Specific Epidemiology
- 8.3.8 Forecast Analysis (2025-2045)
- 8.3.9 Epidemiology Growth Drivers
- 8.3.10 Growth Opportunities
8.4 Latin America
- 8.4.1 Total Prevalence
- 8.4.2 Total Incidence
- 8.4.3 Diagnosed Cases
- 8.4.4 Treated Cases
- 8.4.5 Severity Distribution
- 8.4.6 Age-Specific Epidemiology
- 8.4.7 Gender-Specific Epidemiology
- 8.4.8 Forecast Analysis (2025-2045)
- 8.4.9 Epidemiology Growth Drivers
- 8.4.10 Growth Opportunities
8.5 Middle East & Africa
- 8.5.1 Total Prevalence
- 8.5.2 Total Incidence
- 8.5.3 Diagnosed Cases
- 8.5.4 Treated Cases
- 8.5.5 Severity Distribution
- 8.5.6 Age-Specific Epidemiology
- 8.5.7 Gender-Specific Epidemiology
- 8.5.8 Forecast Analysis (2025-2045)
- 8.5.9 Epidemiology Growth Drivers
- 8.5.10 Growth Opportunities

9. Key Countries Analysis

9.1 United States
- 9.1.1 Total Prevalence
- 9.1.2 Total Incidence
- 9.1.3 Diagnosed Cases
- 9.1.4 Treated Cases
- 9.1.5 Disease Type Distribution
- 9.1.6 Age-Specific Epidemiology
- 9.1.7 Gender-Specific Epidemiology
- 9.1.8 Severity Distribution
- 9.1.9 Forecast Analysis (2025-2045)
9.2 Canada
- 9.2.1 Total Prevalence
- 9.2.2 Total Incidence
- 9.2.3 Diagnosed Cases
- 9.2.4 Treated Cases
- 9.2.5 Disease Type Distribution
- 9.2.6 Age-Specific Epidemiology
- 9.2.7 Gender-Specific Epidemiology
- 9.2.8 Severity Distribution
- 9.2.9 Forecast Analysis (2025-2045)
9.3 Germany
- 9.3.1 Total Prevalence
- 9.3.2 Total Incidence
- 9.3.3 Diagnosed Cases
- 9.3.4 Treated Cases
- 9.3.5 Disease Type Distribution
- 9.3.6 Age-Specific Epidemiology
- 9.3.7 Gender-Specific Epidemiology
- 9.3.8 Severity Distribution
- 9.3.9 Forecast Analysis (2025-2045)
9.4 United Kingdom
- 9.4.1 Total Prevalence
- 9.4.2 Total Incidence
- 9.4.3 Diagnosed Cases
- 9.4.4 Treated Cases
- 9.4.5 Disease Type Distribution
- 9.4.6 Age-Specific Epidemiology
- 9.4.7 Gender-Specific Epidemiology
- 9.4.8 Severity Distribution
- 9.4.9 Forecast Analysis (2025-2045)
9.5 France
- 9.5.1 Total Prevalence
- 9.5.2 Total Incidence
- 9.5.3 Diagnosed Cases
- 9.5.4 Treated Cases
- 9.5.5 Disease Type Distribution
- 9.5.6 Age-Specific Epidemiology
- 9.5.7 Gender-Specific Epidemiology
- 9.5.8 Severity Distribution
- 9.5.9 Forecast Analysis (2025-2045)
9.6 Italy
- 9.6.1 Total Prevalence
- 9.6.2 Total Incidence
- 9.6.3 Diagnosed Cases
- 9.6.4 Treated Cases
- 9.6.5 Disease Type Distribution
- 9.6.6 Age-Specific Epidemiology
- 9.6.7 Gender-Specific Epidemiology
- 9.6.8 Severity Distribution
- 9.6.9 Forecast Analysis (2025-2045)
9.7 Spain
- 9.7.1 Total Prevalence
- 9.7.2 Total Incidence
- 9.7.3 Diagnosed Cases
- 9.7.4 Treated Cases
- 9.7.5 Disease Type Distribution
- 9.7.6 Age-Specific Epidemiology
- 9.7.7 Gender-Specific Epidemiology
- 9.7.8 Severity Distribution
- 9.7.9 Forecast Analysis (2025-2045)
9.8 China
- 9.8.1 Total Prevalence
- 9.8.2 Total Incidence
- 9.8.3 Diagnosed Cases
- 9.8.4 Treated Cases
- 9.8.5 Disease Type Distribution
- 9.8.6 Age-Specific Epidemiology
- 9.8.7 Gender-Specific Epidemiology
- 9.8.8 Severity Distribution
- 9.8.9 Forecast Analysis (2025-2045)
9.9 Japan
- 9.9.1 Total Prevalence
- 9.9.2 Total Incidence
- 9.9.3 Diagnosed Cases
- 9.9.4 Treated Cases
- 9.9.5 Disease Type Distribution
- 9.9.6 Age-Specific Epidemiology
- 9.9.7 Gender-Specific Epidemiology
- 9.9.8 Severity Distribution
- 9.9.9 Forecast Analysis (2025-2045)
9.10 India
- 9.10.1 Total Prevalence
- 9.10.2 Total Incidence
- 9.10.3 Diagnosed Cases
- 9.10.4 Treated Cases
- 9.10.5 Disease Type Distribution
- 9.10.6 Age-Specific Epidemiology
- 9.10.7 Gender-Specific Epidemiology
- 9.10.8 Severity Distribution
- 9.10.9 Forecast Analysis (2025-2045)
9.11 South Korea
- 9.11.1 Total Prevalence
- 9.11.2 Total Incidence
- 9.11.3 Diagnosed Cases
- 9.11.4 Treated Cases
- 9.11.5 Disease Type Distribution
- 9.11.6 Age-Specific Epidemiology
- 9.11.7 Gender-Specific Epidemiology
- 9.11.8 Severity Distribution
- 9.11.9 Forecast Analysis (2025-2045)
9.12 Australia
- 9.12.1 Total Prevalence
- 9.12.2 Total Incidence
- 9.12.3 Diagnosed Cases
- 9.12.4 Treated Cases
- 9.12.5 Disease Type Distribution
- 9.12.6 Age-Specific Epidemiology
- 9.12.7 Gender-Specific Epidemiology
- 9.12.8 Severity Distribution
- 9.12.9 Forecast Analysis (2025-2045)

10. Competitive Landscape

10.1 Epidemiology Intelligence Providers
10.2 Real-World Evidence Providers
10.3 Mental Health Registries and Databases
10.4 Academic Research Institutions
10.5 Public Health Organizations
10.6 Competitive Benchmarking Analysis
10.7 Future Epidemiology Intelligence Trends

11. Company Profiles

11.1 IQVIA Holdings Inc.
- 11.1.1 Overview
- 11.1.2 Financials
- 11.1.3 Mental Health Research Capabilities
- 11.1.4 Epidemiology and Real-World Evidence Portfolio
- 11.1.5 Depression Research Programs
- 11.1.6 Data Analytics Capabilities
- 11.1.7 Strategic Collaborations
- 11.1.8 Recent Developments
11.2 Clarivate Plc
- 11.2.1 Overview
- 11.2.2 Financials
- 11.2.3 Epidemiology Intelligence Solutions
- 11.2.4 Mental Health Research Capabilities
- 11.2.5 Data Analytics Capabilities
- 11.2.6 Strategic Collaborations
- 11.2.7 Recent Developments
11.3 Oracle Health
- 11.3.1 Overview
- 11.3.2 Financials
- 11.3.3 Clinical Data and Epidemiology Solutions
- 11.3.4 Mental Health Data Analytics
- 11.3.5 Real-World Evidence Capabilities
- 11.3.6 Strategic Collaborations
- 11.3.7 Recent Developments
11.4 ICON plc
- 11.4.1 Overview
- 11.4.2 Financials
- 11.4.3 Epidemiology Research Capabilities
- 11.4.4 Mental Health Research Expertise
- 11.4.5 Data Analytics Services
- 11.4.6 Strategic Collaborations
- 11.4.7 Recent Developments
11.5 Syneos Health, Inc.
- 11.5.1 Overview
- 11.5.2 Financials
- 11.5.3 Epidemiology and RWE Capabilities
- 11.5.4 Mental Health Research Expertise
- 11.5.5 Strategic Collaborations
- 11.5.6 Recent Developments
11.6 Optum, Inc.
- 11.6.1 Overview
- 11.6.2 Financials
- 11.6.3 Healthcare Database Capabilities
- 11.6.4 Population Health Analytics
- 11.6.5 Mental Health Research Programs
- 11.6.6 Strategic Collaborations
- 11.6.7 Recent Developments
11.7 Veradigm Inc.
- 11.7.1 Overview
- 11.7.2 Financials
- 11.7.3 Real-World Data Assets
- 11.7.4 Epidemiology Research Capabilities
- 11.7.5 Mental Health Analytics Programs
- 11.7.6 Strategic Collaborations
- 11.7.7 Recent Developments
11.8 Truveta, Inc.
- 11.8.1 Overview
- 11.8.2 Financials
- 11.8.3 Population Health Data Resources
- 11.8.4 Mental Health Research Capabilities
- 11.8.5 Epidemiology Analytics Solutions
- 11.8.6 Strategic Collaborations
- 11.8.7 Recent Developments
11.9 Komodo Health, Inc.
- 11.9.1 Overview
- 11.9.2 Financials
- 11.9.3 Healthcare Mapping Capabilities
- 11.9.4 Mental Health Data Analytics
- 11.9.5 Epidemiology Intelligence Solutions
- 11.9.6 Strategic Collaborations
- 11.9.7 Recent Developments
11.10 Cegedim Health Data
- 11.10.1 Overview
- 11.10.2 Financials
- 11.10.3 Epidemiology Database Capabilities
- 11.10.4 Mental Health Research Programs
- 11.10.5 Real-World Evidence Solutions
- 11.10.6 Strategic Collaborations
- 11.10.7 Recent Developments